Monday, 3:30 pm, 1003 Malott (unless specified)
|Date||Presenter / Topic|
|January 23||No seminar (Analytical faculty meeting)|
|January 30||Joe Siegel, Lunte Research Group
"Development of Microfluidic-Based Methods for Monitoring Intracellular Nitrosative and Oxidative Stress"
|February 6||Dr. Camila Campos, Postdoctoral Research Associate, Soper Research Group
"Extraction of cell-free DNA on microfluidic devices"
The study of cell-free DNA (cfDNA) became attractive after the discovery of differences in cfDNA concentration in blood from healthy individuals and cancer patients. Recent discoveries relate the levels and characteristics of cfDNA with other conditions such as stroke, cardiac arrest, sepsis, trauma, autoimmune diseases, parasitic infections, complications derived from overexercise, diabetes and hypertension. It is also a non-invasive alternative prenatal exam. However, the cost, time and expertise involved in cfDNA analysis still limit its application. Microfluidics benefits from the flexibility afforded by microscale and can fulfill these requirements. While reliable miniaturized detection and analysis of DNA are broadly discussed in the literature, few papers approach the isolation and enrichment of cfDNA. In this seminar, we will discuss the importance of cell-free DNA and present some of our achievements on the developing of a new microfluidic device to solid-phase extraction of cell-free DNA.
|February 13||Dr. Matt Jackson, Postdoctoral Research Associate, Soper Research Group
Title: "Microfluidics for Monitoring Relapse in Patients with Acute Myeloid Leukemia"
We report a highly sensitive microfluidic assay to detect minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) that samples peripheral blood to search for circulating leukemic cells (CLCs). Antibodies immobilized within three separate microfluidic devices affinity-selected CLC subpopulations directly from peripheral blood without requiring pre-processing. The microfluidic devices targeted CD33, CD34, and CD117 cell surface antigens commonly expressed by AML leukemic cells so that each subpopulation's CLC numbers could be tracked to determine the onset of relapse. Staining against aberrant markers (e.g. CD7, CD56) identified low levels (11–2684 mL−1) of CLCs. The commonly used platforms for the detection of MRD for AML patients are multi-parameter flow cytometry (MFC), typically from highly invasive bone marrow biopsies, or PCR from blood samples, which is limited to <50% of AML patients. In contrast, the microfluidic assay is a highly sensitive blood test that permits frequent sampling for >90% of all AML patients using the markers selected for this study (selection markers CD33, CD34, CD117 and aberrant markers such as CD7 and CD56). We present data from AML patients after stem cell transplant (SCT) therapy using our assay. We observed high agreement of the microfluidic assay with therapeutic treatment and overall outcome. We could detect MRD at an earlier stage compared to both MFC and PCR directly from peripheral blood, obviating the need for a painful bone marrow biopsy. Using the microfluidic assay, we detected MRD 28 days following one patient‘s SCT and the onset of relapse at day 57, while PCR from a bone marrow biopsy did not detect MRD until day 85 for the same patient. Earlier detection of MRD in AML post-SCT enabled by peripheral blood sampling using the microfluidic assay we report herein can influence curative clinical decisions for AML patients.
|February 20||Kasun Imaduwage, Desaire Research Group
Title: "High Throughput Screening (HTS) of Potential Lead Compounds for Target Proteins with No False Identifications Using LC/MS"
|February 27||Hasitha Mudiyanselage, Schoeneich Research Group
Title: "Fragmentation of Biotherapeutics by Tungstates and Peroxotungstates"
|March 6||Brittany DeWitt, Dunn Research Group
Title: "Single Molecule Analysis of Biomembrane Heterogeneity"
|March 13||Divya Lella, Zeng Research Group
Title: "Multiplexed Microfluidic Digital ELISA towards Single Cell Analysis"
|March 20||No seminar (Spring Break)|
|March 27||Xin Zhou, Zeng Research Group
Title: "Microfluidic microRNA detection for liquid-biopsy based cancer diagnosis"
|April 3||No seminar (ACS National Meeting)|
|April 10||Jude Lakbub, Desaire Research Group
|April 17||Tom Field, M. Johnson Research Group
|April 24||Rachel Gehringer, M. Johnson Research Group
|May 1||No seminar (Instrumental Analysis student presentations)|